Global Gynecology Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

News provided by

Sep 16, 2021, 16:30 ET

DUBLIN, Sept. 16, 2021 /PRNewswire/ -- Gain comprehensive access to over 400 gynecology deal records from this report "Global Gynecology Partnering 2010-2021: Deal Trends, Players and Financials" that has been added to ResearchAndMarkets.com's offering.

This report provides a full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Gynecology partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Gynecology partnering agreement structure
Gynecology partnering contract documents
Top Gynecology deals by value
Most active Gynecology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.

The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gynecology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gynecology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gynecology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gynecology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gynecology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gynecology partnering deals by specific Gynecology target announced since 2010. The chapter is organized by specific Gynecology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gynecology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gynecology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gynecology technologies and products.

Report Scope

Global Gynecology Partnering 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to Gynecology trends and structure of deals entered into by leading companies worldwide.

Global Gynecology Partnering 2010 to 2021 includes:

Trends in Gynecology dealmaking in the biopharma industry since 2010
Analysis of Gynecology deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Gynecology deal contract documents
Comprehensive access to over 400 Gynecology deal records
The leading Gynecology deals by value since 2010
Most active Gynecology dealmakers since 2010

The report includes deals for the following indications: Adenomyosis, Cervical Intraepithelial Neoplasia (CIN), Endometriosis, Fibroids, Human papillomavirus (HPV), Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease, Polycystic ovary syndrome, Pre-menstrual syndrome, Prolapse, Amenorrhea, Dysmenorrhea, Pelvic pai, Vaginitis, plus other gynecological indications.

In Global Gynecology Partnering 2010 to 2021, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gynecology Partnering 2010-2021 report provides comprehensive access to available deals and contract documents for over 400 gynecology deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gynecology dealmaking
2.1. Introduction
2.2. Gynecology partnering over the years
2.3. Gynecology partnering by deal type
2.4. Gynecology partnering by industry sector
2.5. Gynecology partnering by stage of development
2.6. Gynecology partnering by technology type
2.7. Gynecology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Gynecology partnering
3.1. Introduction
3.2. Disclosed financials terms for Gynecology partnering
3.3. Gynecology partnering headline values
3.4. Gynecology deal upfront payments
3.5. Gynecology deal milestone payments
3.6. Gynecology royalty rates

Chapter 4 - Leading Gynecology deals and dealmakers
4.1. Introduction
4.2. Most active in Gynecology partnering
4.3. List of most active dealmakers in Gynecology
4.4. Top Gynecology deals by value

Chapter 5 - Gynecology contract document directory
5.1. Introduction
5.2. Gynecology partnering deals where contract document available

Chapter 6 - Gynecology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Gynecology therapeutic target

Appendices

Companies Mentioned

23andMe
Abbvie
Accord Healthcare
Acerus
Advaxis
Adynxx
AEterna Zentaris
Agency for Healthcare Research and Quality
Agile Therapeutics
AirStrip Technologies
Albion
Allakos
Alvogen
American Dental Association
Amgen
Amos Gazit
ANI Pharmaceuticals
ApolloBio
Arbor Pharmaceuticals
Arc Medical Design
Ascend Therapeutics
ASKA Pharmaceuticals
Aspen Dental
ASPiRA Labs
AstraZeneca
Austrian Research Promotion Agency
Avion Pharmaceuticals
Aytu BioScience
Back Bay Scientific
Bavarian Nordic
Bayer
Bayer Healthcare
Baylor College of Medicine
Beckman Coulter
Beijing Genomics Institute (BGI)
Besins Healthcare
Bill and Melinda Gates Foundation
Biocon
Biomnis
Biotech Inc
BL&H
Bluebird Bio
BMV Medica
Boston Scientific
Bristol-Myers Squibb
California Institute for Biomedical Research
Celmatix
Center for Human Genetics and Laboratory Medicine
Chinese Academy of Sciences
Chun Fo Pharmaceutical
Cipla Medpro
ClearSpec
Clinigen
CNC Biotech
Co-Diagnostics
Cocrystal Pharma
CommonSense
Common Sense
Consortia Health
Control Flo Medical
Cooper Companies
Coriell Life Sciences
CR Pharma
CVC Capital Partners
Cynosure
Debiopharm
DIAsource ImmunoAssays
Dilafor
Distal Access
Duchesnay
Duke University
DySIS Medical
Easton Pharmaceuticals
Egalet
El.En
Elanix Biotechnologies
EMD Serono
Emory University
EndoCeutics
European Board and College of Obstetrics and Gynaecology
European Organization for Research and Treatment of Cancer
European Union Regional Development Fund
Evestra
Evotec
Expedeon
Famy Care
Ferring Pharmaceuticals
Flo Health
Fogarty Institute for Innovation
Foresee Pharmaceuticals
Fougera Pharmaceuticals
Fuji Pharma
Genea Biomedx
Genoma
Genome Medical
German Cancer Research Center
Gilead Sciences
GlaxoSmithKline
GOG Foundation
Golden Valley Development
Good Start Genetics
Grunenthal
Guided Therapeutics
Gynica
Halt Medical
Hammock Pharmaceuticals
HealthNet
Helix
Helix BioPharma
Hologic
Hookipa Biotech
Hope Medicine
HTG Molecular Diagnostics
Igantia Therapeutics
iGenomix
Illumina
Imaxio
IncellDx
InnerOptic Technology
Innovus Pharmaceuticals
Inovio Pharmaceuticals
Intuitive Surgical
INVO Bioscience
Irvine Scientific
IsoRay
ITEM Medical Technologies
IviGen
Janssen Pharmaceuticals
Johns Hopkins University
Joylux
Karolinska Institute
Kissei Pharmaceutical
Kite Pharma
Knight Therapeutics
Kyoto University
Laboratory Corporation of America
Laccure
Lake Consumer Products
Lee's Pharmaceutical
LFB Biotechnologies
LifeCodexx
Lumara Health
Lumir Lab
Massachusetts General Hospital
McKesson
MD Anderson Cancer Center
MDNA Life Sciences
Meda
MEDCIS Pathlabs
Medical University of South Carolina
Medical University South Carolina
MediCare International
MediGene
MedikorPharma
MedImmune
Medinova
MedTech For Solutions
Medtronic
Mel-Mont Medical
MenoGeniX
Merck and Co
Merck KGaA
Merck Serono
Merus Labs International
MilanaPharm
Millendo Therapeutics
Ministry of Health (Turkey)
Mission Pharmacal
Mithra Pharmaceuticals
Mitsubishi Tanabe Pharma
Morphic Therapeutic
MSD
Mundipharma
MyBiotics Pharma
Mylan Laboratories
Myovant Sciences
Myrtle Potter & Company
Naka International
Natera
National Institute for Public Health and the Environment
National Institute on Aging
National Institutes of Health
Neoteric Technology
NextGen LifeLabs
Nobelpharma
Norgine
Northwestern University
Novation
Noven Pharmaceuticals
Novogene
NX Prenatal
OBP Medical
ObsEva
Olympus
OncoSec Medical
Oncotest
Oral Cancer Foundation
OvaGene Oncology
Oxford MEstar
Patient-Centered Primary Care Collaborative (PCPCC)
PaxGenBio
PCOS Challenge
PCOS Diva
PDS Biotechnology
Peking University
Perinatal Quality Foundation
PerkinElmer
Perrigo
Pfizer
PharmaJet
Pharmanest
Pharma Solutions Peru
Psyche Systems
Radius Health
Rebiotix
Recipharm
Reproductive Health Science
Reprogenetics
rEVO Biologics
Roche
Romark Laboratories
Royal Philips Electronics
Sanofi
Sanofi-Pasteur
Scholar Rock
Selecta Biosciences
Shandong Yaohua Medical Instrument
Shenghuo Medical
Shionogi
Shire Pharmaceuticals
Sims IVF
Sincopharm
Sirio Pharma
Skolkovo Foundation
Smith & Nephew
Smiths Medical
Society For Reproductive Investigation
Society of Gynecologic Oncology
SRI International
Starpharma
Strainprint Technologies
Sun Pharmaceutical
Surgicorp
Syn-The-All Pharmaceutical
SynteractHCR
Takeda Pharmaceutical
Tec-Pharma
Telenatal
Tesaro
Tessa Therapeutics
Teva Pharmaceutical Industries
Teva Pharmaceuticals USA
Theramex
TherapeuticsMD
Thermo Fisher Scientific
Transgene
Trimel Pharmaceuticals
Trivector Biomed
Trophogen
twoXAR
Unified Women's Clinical Research
University College Dublin Conway Institute
University Magna Graecia
University of Hong Kong
University of Michigan
University of Oxford
University of Siena
Upsher-Smith
Vaccibody
Valeo Pharma
Vertical Pharmaceuticals
Viramal
Virtus Health
VolitionRX
Wayne State University
Wellmed
Windsor Pharmaceuticals
Womens Choice Pharmaceuticals
Wuxi Apptec Laboratory Services
Xbrane Bioscience
Xisle Pharma Ventures Trust
ZenTech
Zhengzhou University
Zoetis

For more information about this report visit https://www.researchandmarkets.com/r/ip2agt

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets